Great Point Partners’s Vaxcyte PCVX Stock Holding History

Great Point Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-115,517	Closed	-$4.36M	–	34
2025 Q1	$4.36M	Buy	+115,517	New	+$9.24M	2.31%	19
2024 Q1	–	Sell	-360,000	Closed	-$22.6M	–	39
2023 Q4	$22.6M	Sell	360,000 -171,211	-32%	-$8.89M	3.85%	10
2023 Q3	$27.1M	Sell	531,211 -58,000	-10%	-$2.86M	4.93%	4
2023 Q2	$29.4M	Sell	589,211 -70,000	-11%	-$3.32M	5.76%	3
2023 Q1	$24.7M	Sell	659,211 -140,789	-18%	-$5.97M	4.85%	6
2022 Q4	$38.4M	Buy	800,000 +200,000	+33%	+$7.85M	7.52%	1
2022 Q3	$14.4M	Sell	600,000 -385,153	-39%	-$9.76M	3.47%	11
2022 Q2	$21.4M	Buy	985,153 +100,000	+11%	+$2.31M	5.14%	6
2022 Q1	$21.4M	Buy	885,153 +385,153	+77%	+$8.41M	5.17%	10
2021 Q4	$11.9M	Buy	500,000 +401,939	+410%	+$9.35M	2.64%	16
2021 Q3	$2.49M	Buy	+98,061	New	+$2.38M	0.58%	31

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Great Point Partners's PCVX Position: Q2 2025 in Review

Great Point Partners sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 115,517 shares — an estimated $4.36M sold.

Great Point Partners first reported a position in PCVX in Q3 2021 and held it in 11 quarters. The position peaked at $38.4M in Q4 2022. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Great Point Partners reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Great Point Partners sold 115,517 Vaxcyte shares in Q2 2025, an estimated $4.36M.
Great Point Partners first reported a position in Vaxcyte in Q3 2021 and held it in 11 quarters.
Great Point Partners's Vaxcyte position peaked at $38.4M in Q4 2022.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Great Point Partners's 13F filing for Q2 2025, filed 14 Aug 2025.